BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29253109)

  • 1. Induction of Complete Remission by Azacitidine in a Patient with Myelodysplastic Syndrome-Associated Inflammatory Bowel Disease.
    Kono M; Komeda Y; Sakurai T; Okamoto A; Minaga K; Kamata K; Hagiwara S; Inoue H; Enoki E; Matsumura I; Watanabe T; Kudo M
    J Crohns Colitis; 2018 Mar; 12(4):499-502. PubMed ID: 29253109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.
    Kono M; Sakurai T; Okamoto K; Nagai T; Komeda Y; Kashida H; Minaga K; Kamata K; Takenaka M; Hagiwara S; Watanabe T; Nishida N; Enoki E; Inoue H; Matsumura I; Kudo M
    Intern Med; 2019 Jul; 58(14):2029-2033. PubMed ID: 30996178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
    Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
    J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Unidentified Inflammatory Disease Induced by Azacitidine Therapy for Myelodysplastic Syndrome].
    Inagaki S; Tamai Y; Yoshizawa M; Sato S; Kanbe E; Tanaka E
    Gan To Kagaku Ryoho; 2015 Nov; 42(11):1443-6. PubMed ID: 26602409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous occurrence of inflammatory bowel disease and myelodysplastic syndrome due to chromosomal abnormalities in bone marrow cells.
    Nakamura F; Watanabe T; Hori K; Ohara Y; Yamashita K; Tsuji Y; Ueda Y; Mikami S; Nakase H; Chiba T
    Digestion; 2009; 79(4):215-9. PubMed ID: 19390193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
    Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
    Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.
    Tanaka H; Shimizu N; Tougasaki E; Kawajiri C; Hashimoto S; Takeda Y; Sakai S; Takeuchi M; Ohwada C; Sakaida E; Takagi T; Nakaseko C
    Int J Hematol; 2013 Apr; 97(4):520-4. PubMed ID: 23519573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Azacitidine treatment for acute myeloid leukemia with myelodysplasia-related changes during peritoneal dialysis].
    Omatsu T; Udaka K; Shibata H; Sekimoto E; Ozaki S
    Rinsho Ketsueki; 2017; 58(12):2369-2374. PubMed ID: 29332868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].
    Mishima M; Makita M; Sando Y; Yamamoto Y; Shiote Y; Hara Y; Yamamoto K; Imajo K
    Rinsho Ketsueki; 2015 Jan; 56(1):35-7. PubMed ID: 25745966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.
    Sébert M; Komrokji RS; Sekeres MA; Prebet T; Cluzeau T; Santini V; Gyan E; Sanna A; Ali NH; Hobson S; Eclache V; List A; Fenaux P; Adès L
    Leuk Res; 2017 Dec; 63():72-77. PubMed ID: 29112938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Case of Myelodysplastic Syndrome with Intestinal Behçet's Disease-Like Symptoms Treated by Prednisolone and Azacitidine.
    Endo M; Sekikawa A; Tsumura T; Maruo T; Osaki Y
    Am J Case Rep; 2015 Nov; 16():827-31. PubMed ID: 26590106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
    Adès L; Itzykson R; Fenaux P
    Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment with azacitidine for a patient with relapsed myelodysplastic syndrome after cord blood transplantation].
    Ueda S; Miyakoshi S; Chizuka A; Kojima R; Ogasawara T; Miyamoto K
    Rinsho Ketsueki; 2013 Dec; 54(12):2177-81. PubMed ID: 24452149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myelodysplastic syndrome with rapid disease progression after withdrawal of treatment with azacitidine].
    Ueda H; Yoshida M; Kanashima H; Nakao T; Sugiyama H; Yamane T
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):875-7. PubMed ID: 25131875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a 5-day regimen of azacitidine for patients with high-risk myelodysplastic syndromes.
    Fujimaki K; Miyashita K; Kawasaki R; Tomita N
    Eur J Haematol; 2016 Sep; 97(3):228-31. PubMed ID: 26613362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy.
    Takaoka K; Hangaishi A; Ito A; Morioka T; Kida M; Usuki K
    Intern Med; 2014; 53(19):2241-3. PubMed ID: 25274238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
    Inoue A; Kawakami C; Takitani K; Tamai H
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):e322-4. PubMed ID: 24608072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Azacitidine for Therapy-Related Myelodysplastic Syndrome Following Oxaliplatin (L-OHP)Therapy for Metastatic Rectal Cancer].
    Matsui T; Sakamoto N; Doi A; Fujii T; Ohno N; Sahara N; Irie S
    Gan To Kagaku Ryoho; 2018 Aug; 45(8):1201-1203. PubMed ID: 30158420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.
    Ozbalak M; Cetiner M; Bekoz H; Atesoglu EB; Ar C; Salihoglu A; Tuzuner N; Ferhanoglu B
    Hematol Oncol; 2012 Jun; 30(2):76-81. PubMed ID: 21387357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.